Lozovaya, N <br/><br/>
GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease.  [electronic resource] 

 -  Nature communications  04 2018 
 - 1422 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2041-1723 
<br/><br/><label>Standard No.: </label>10.1038/s41467-018-03802-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetylcholine--metabolism<br/>Action Potentials--drug effects<br/>Animals<br/>Bumetanide--pharmacology<br/>Chlorides--metabolism<br/>Cholinergic Agents--metabolism<br/>Cholinergic Neurons--drug effects<br/>Corpus Striatum--drug effects<br/>Dopamine--deficiency<br/>Gene Expression Regulation<br/>Glutamate Decarboxylase--genetics<br/>Humans<br/>Inhibitory Postsynaptic Potentials--drug effects<br/>Interneurons--drug effects<br/>Ion Transport<br/>LIM-Homeodomain Proteins--genetics<br/>Mice<br/>Mice, Transgenic<br/>Nerve Tissue Proteins--genetics<br/>Neuronal Plasticity--drug effects<br/>Parkinson Disease, Secondary--genetics<br/>Patch-Clamp Techniques<br/>Sodium Potassium Chloride Symporter Inhibitors--pharmacology<br/>Solute Carrier Family 12, Member 2--genetics<br/>Transcription Factors--genetics<br/>Vesicular Inhibitory Amino Acid Transport Proteins--genetics<br/>gamma-Aminobutyric Acid--metabolism